Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$19.41 USD

19.41
3,595,288

+0.74 (3.96%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $19.40 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio

NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.

Stryker's (SYK) Trauma & Extremities Arm Unveils New Product

The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.

Align Technology (ALGN) Launches Professional Whitening System

Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.

OPKO Health (OPK) Forms JV, Establishes Presence in China

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities

Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.

Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes

Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.

Here's Why You Should Invest in Charles River (CRL) Now

Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

LHC Group (LHCG) to Boost Nationwide Presence With New Buyout

LHC Group's (LHCG) deal win enables the company to acquire home health, hospice and therapy assets in 22 states.

Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes

Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.

Omnicell (OMCL) New Buyout Expands Patient Engagement Suite

With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.

NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone

NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.

Here's Why You Should Retain National Vision (EYE) For Now

Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

Teleflex (TFX) Real-World Data Outcome Supports UroLift System

Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.

Kinjel Shah headshot

7 Low Price-to-Book Stocks to Buy in September

The P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

Syneos Health (SYNH) Enhances Clinical Trials With New Pact

Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.

Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge

Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.

NVST vs. BSX: Which Stock Should Value Investors Buy Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

SmileDirectClub (SDC) Struggles With New Markets, High Debt

SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System

Thermo Fisher's (TMO) Nano-Capillary and Micro-Flow LC Systems will benefit principal investigators, laboratories and proteomics researchers in academia, biopharma and contract research organizations.